

Immunology and Inflammation

Having worked on more than 320 clinical studies in immunology and inflammation over the past five years involving more than 90,000 patients across 11,000 sites globally, you can be confident that regardless of your study's scale or scope, we have the expertise you need to make it a success.

Preview our capabilities

- Vast experience in both major and niche disorders
- Global scale with local scope
- Robust site relationships
- Experienced medical monitors and CRAs
- Dedicated project leaders
- Consulting capabilities
- Cutting-edge technology (e.g., TrialEAS™)

With one in three people affected and billions of dollars in healthcare costs incurred annually, chronic inflammatory diseases represent the greatest therapeutic burden both in terms of suffering and expense. But medicines for many such diseases treat the symptoms rather than the underlying cause. These unmet needs combined with the field's rapid progress has led to R&D pipelines overflowing with immune system-focused products. However, developing such products requires expert knowledge. Not only do many of these conditions affect various organ systems (presenting challenges in diagnosis and outcome measures), the nature of the products (e.g., biologics) also necessitates a partner with specialized operational and regulatory experience. That's why so many companies turn to INC Research – the leading CRO in inflammation and immunology research.

As a therapeutically focused organization, our expertise in immunological and inflammatory disorders may come as no surprise. Because we've been helping companies develop such products for more than 15 years, we've developed an extensive global network of experienced sites along with a team of highly knowledgeable experts. And because every one of our projects is conducted using our proven Trusted Process®, you can be sure of high-quality, defensible data at every stage of your product's lifecycle.

Preview our vast experience

Disorders

- Allergies
- Ankylosing spondylitis
- Asthma
- Bursitis
- Celiac disease
- Chronic pain
- COPD
- Crohn's disease
- Dermatomyositis
- Gout
- Idiopathic thrombocytopenic purpura
- Immune deficiency
- Inflammatory bowel disease
- Osteoarthritis
- Paroxysmal nocturnal hemoglobinuria
- Psoriasis
- Psoriatic arthritis
- Rheumatoid arthritis (RA) (adult and juvenile)
- Sarcoidosis
- Scleroderma
- Sjögren's syndrome
- Systemic lupus erythematosus (SLE)
- Systemic sclerosis
- Tendonitis
- Ulcerative colitis
- Vasculitis

Drugs

- Anti-CD4 therapies
- BAFF antagonists
- B-cell targeted therapies
- C5a inhibitors
- CCR1 antagonist
- COX-2 inhibitors
- COX/LOX dual inhibitors
- Glucocorticoids
- H4R antagonists
- IL-1 receptor antagonists
- IL-6 antagonists
- Immunosuppressive agents
- iNOS inhibitors
- JAK-3 inhibitor
- Methotrexate
- NSAIDs
- p38 MAP kinase inhibitors
- PDE4 inhibitors
- Pyrimidine synthesis inhibitors
- sPLA2 inhibitors
- Syk kinase inhibitor
- TLR7/TLR9 Inhibitors
- TNF antagonists
- Type 1 IFN antagonists

Site expertise

Patient enrollment is often a major time-limiting factor for clinical studies, which is why INC Research places such a great emphasis on getting recruitment right. According to ClinicalTrials.gov, there are more than 1,000 studies on-going for rheumatoid arthritis (RA) alone. This means that both patients and sites have a choice when it comes to which studies they choose to participate in. However, at INC Research, we recognize this issue, which is why we pride ourselves on forging strong relationships with sites from South America to South Africa, as well as founding our recruitment strategies on sound patient insights and local demographic knowledge. In addition, because we understand the challenges presented by working with complex substances and less-experienced sites, we ensure thorough site training prior to a project's start through initiatives such as our QuickStart® camp to fortify site staff with the knowledge they need to make your study a success.

From advice to implementation

We know that to provide an efficient solution to your clinical development needs, integration is key. That's why we develop integrated strategies that combine all our capabilities under one program, ensuring all relevant indication/therapy-related guidance and safety considerations are taken into account during every stage of your product's lifecycle, from study consultation to trial implementation.

The right tools for the job

No matter the job, utilizing the right tools is essential. For example, by leveraging TrialEAS™, our proprietary electronic endpoint adjudication system, we're able to assist investigators in the patient selection process by quickly confirming patient eligibility. We also continually assess customer needs to proactively develop new tools. For instance, we recently collaborated with a key opinion leader to develop a joint assessment module for use in RA studies. This new tool allowed us to provide the required site staff training quickly and cost effectively.

Turning intuitive RA insights into real results

When a U.S.-based biopharmaceutical company required a partner for two Phase IIB RA studies, it knew the heavily-saturated clinical trial environment for RA would present recruitment difficulties and turned to us for help. Using qualified patient insights and excellent communication pathways, we created a dedicated network of team members to identify potential challenges and plan accordingly. By the end of the project, the value of our expertise was clear – one study completed three months ahead of schedule and the other, two months ahead.

Using innovation to ensure SLE study enrollment success and quality data

To help a leading U.S.-based biotechnology company recruit more than 200 systemic lupus erythematosus (SLE) patients for a Phase II study, we were asked to support their recruitment efforts. However, ensuring the right patients were enrolled was expected to be challenging due to the complex nature of the condition. That's why we created a robust strategy built on sound patient understanding and solid data, as well as employing TrialEAS™ to ensure the right patients were identified quickly and easily. And by uploading and sending patient data to the medical monitor electronically, geographical barriers were removed along with the need for expensive and time-consuming document shipments. In fact, enrollment was ultimately completed four months ahead of schedule – proof that when it comes to patient insights, INC Research has the expertise you need.

For more information

about INC Research's capabilities in immunology and inflammation clinical research, please contact us at info@incresearch.com or at one of the numbers below:

North America

Raleigh, NC, United States. Tel: +1 919 876 9300

Europe/Middle East/Africa

Winnersh, United Kingdom. Tel: +44 118 933 5300

Asia/Pacific

Port Adelaide, Australia. Tel: +61 8 8447 3500

Beijing, China. Tel: +86 10 5809 2300

Gurgaon, India. Tel: +91 124 464 2400

Latin America

Mexico City, Mexico. Tel: +52 55 2169 0300

Corporate Headquarters

3201 Beechleaf Court, Suite 600, Raleigh, NC 27604-1547 Tel: +1 919 876 9300
Email: info@incresearch.com www.incresearch.com



Therapeutic Foresight.
Trusted Results™